Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAT8881 in acute migraine
NCT04153409Phase 2Completed
- Sponsor
- Lateral Pharma
- Start
- Sep 2019
- Primary completion
- Feb 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LAT8881 in migraine (2 arms), sponsored by Lateral Pharma. Primary endpoint: Change in Migraine Headache Pain Score From Time of Dosing at 24 hours. Started Sep 2019; status: completed.
02
Drugs
LAT8881
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04153409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04153409.